U.S. markets closed

Alkermes plc (ALKS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.00-0.01 (-0.05%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close22.01
Open22.07
Bid21.95 x 1000
Ask22.63 x 2900
Day's Range21.94 - 22.41
52 Week Range14.52 - 23.92
Volume3,003,267
Avg. Volume1,333,569
Market Cap3.53B
Beta (5Y Monthly)0.98
PE Ratio (TTM)N/A
EPS (TTM)-0.59
Earnings DateJul 27, 2021 - Aug 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.11
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why Shares of Alkermes Rose 18% Last Month
    Motley Fool

    Why Shares of Alkermes Rose 18% Last Month

    Shares of Alkermes (NASDAQ: ALKS) climbed 17.8% in April, according to S&P Global Market Intelligence. Alkermes announced a partnership to fight ovarian cancer, reported earnings that beat Wall Street estimates, and reached an agreement with an activist hedge fund that had been agitating for changes. Early in the month, the company announced it would advance the combination of nemvaleukin -- its drug that expands tumor-killing immune cells -- with Merck's Keytruda, to phase 3 trials.

  • Motley Fool

    Want to Make Money in Biotech? Do This First

    Biotech investors live and die by the binary news events generated by the drugmakers they invest in. Heron Therapeutics (NASDAQ: HRTX), for instance, is awaiting a decision from the Food and Drug Administration about its candidate HTX-011 for use in post-operative pain. Likewise, Alkermes (NASDAQ: ALKS) expects an FDA decision on its schizophrenia and bipolar treatment ALKS3831 on or before June 1.

  • Alkermes to Take Part in the BofA Securities 2021 Virtual Healthcare Conference
    PR Newswire

    Alkermes to Take Part in the BofA Securities 2021 Virtual Healthcare Conference

    Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the BofA Securities 2021 Healthcare Conference on Wednesday, May 12, 2021 at 2:45 p.m. ET (7:45 p.m. BST). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.